Pulmonary Hypertension, Quality of Life and Psychosocial Factors

Study Overview
=================
Brief Summary
-----------------
The investigators aim to : describe and analyse psychological characteristics, cognitive factors and representations in patients with Pulmonary Hypertension, a rare disease. assess the psychological characteristics impact on quality of life, check the association between disease and QoL evolution, and the variability of QoL parameters over severity class changes and follow-up

Detailed Description
-----------------
PAH is a rare, and severe disease, potentially mortal, affecting preferentially young subjects. The knowledge and the international literature, as regards the quality of life, the expectations, the needs and the psychosocial characteristics of patients with PAH, are non-existent. But it is known that the persons affected by rare diseases are more vulnerable, on the psychological, social, economic and cultural planIn all the stages of the treatment, patients with PAH are confronted with heavy psychosocial situations, in a context of vital risk, with exceptional medicinal treatments (intravenous administration at home). QoL might be differently affected by these changes according to situational and dispositional psychological dimensions. the predictive role of these characteristics on the current and later quality of life, as well as the impact of diverse cognitive mediators and strategies to cope with the disease, should be investigated.The respiratory diseases department of the Montpellier hospital is regional competence center for PAH in Languedoc-Roussillon, under the aegis of the national reference center (the respiratory diseases department of Antoine Béclère hospital, Le Petit-Clamart).

Official Title
-----------------
Pulmonary Hypertension: Impact of the Evolution of a Rare Disease on the Quality of Life and Role of Variables Psychosocial as Predictive of the Current and Later Quality of Life

Conditions
-----------------
Pulmonary Hypertension

Intervention / Treatment
-----------------
* Behavioral: Evaluation of quality of life


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with PAH Patients stable since 3 months Patients with a severity of class I to IV Patients aged between 18 and 80 years Patients no psychological follow-up at the competence center. Exclusion Criteria: Patients unable to give his accordance Patients unable to understand the aim of the study Patients with recents psychiatrics disorders Patients with problems of understanding the tests of the study Drug users or drinkers Pregnant or women without efficacy contraception Patient without freedom by administration decision Patient in exclusion period Patient without french insurance Adult protected by the law

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients with pulmonary hypertension<br> | Behavioral: Evaluation of quality of life<br>* -Psychological interviews-Questionaires : HAD, STAI, CHIP, MHLC, WCC, SSQ scales-Quality of life : SF-36<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Descriptive analysis of psychological characteristics on PAH patients | The descriptive analysis of psychological characteristics (anxiety, depression, social support, coping, control beliefs) is evaluated at entry and at one year. These psychological characteristics are evaluated by score of psychological questionnaires. | 36 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Psychological characteristics impact on Quality of life | The quality of life is measured by the score of the SF 36, the stage of the disease is codified by the NYHA, Qualitative and quantitative analysis of contents of the audio bands by the psychologist implicated to this study. | 36 months | 
| Association between disease and Quality of life evolution | The quality of life is measured by the score of the SF 36, the stage of the disease is codified by the NYHA, Qualitative and quantitative analysis of contents of the audio bands by the psychologist implicated to this study. | 36 months | 
| Variability of Quality of life parameters over severity class changes and follow-up | The quality of life is measured by the score of the SF 36, the stage of the disease is codified by the NYHA, Qualitative and quantitative analysis of contents of the audio bands by the psychologist implicated to this study. | 36 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pulmonary Hypertension, Quality of life, Coping, Depression, Anxiety, Social support, Control beliefs